CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.
Employees - 281,
CEO - Dr. Xingjuan Chao Ph.D.,
Sector - Healthcare,
Country - US,
Market Cap - 532.47M
Ticker | CBLL |
Index | RUT |
Curent Price | 14.85 |
Change | 2.45% |
Market Cap | 532.47M |
Average Volume | 242.73K |
Income | - |
Sales | - |
Book Value/Share | 5.33 |
Cash/Share | 5.42 |
Dividend Est | - |
Dividend TTM | - |
Dividend Ex-Date | - |
Employees | 281 |
Moving Avg 20days | -16.18% |
Moving Avg 50days | -27.95% |
Moving Avg 200days | -37.71% |
Shares Outstanding | 35.85M |
Earnings Date | Feb 25 AMC |
Inst. Ownership | 46.11% |
Price/Earnings | - |
Forwad P/E | - |
PE Growth | - |
Price/Sales | - |
Price/Book | 2.78 |
Price/Cash | 2.74 |
Price/FCF | - |
Quick Ratio | 16.05 |
Current Ratio | 16.59 |
Debt/Equity | 0.11 |
Return on Assets | - |
Return on Equity | - |
Return on Investment | - |
Gross Margin | - |
Ops Margin | - |
Profit Margin | - |
RSI | 38.65 |
BETA(β) | - |
From 52week Low | 48.30% |
From 52week High | -54.67% |
EPS | - |
EPS next Year | -1.34 |
EPS next Qtr | -0.41 |
EPS this Year | 52.00% |
EPS next 5 Year | 35.69% |
EPS past 5 Year | - |
Sales past 5 Year | 59.59% |
EPS Y/Y | - |
Sales Y/Y | - |
EPS Q/Q | - |
Sales Q/Q | - |
Sales Surprise | 5.59% |
EPS Surprise | -25.79% |
ATR(14) | 1.82 |
Perf Week | 33.14% |
Perf Month | -28.06% |
Perf Quarter | -26.33% |
Perf Year | - |
Perf YTD | -42.64% |
Target Price | 33.00 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer